Literature DB >> 26666929

Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival.

Nathaniel J Rhodes1, Joseph L Kuti2, David P Nicolau3, Scott Van Wart4, Anthony M Nicasio5, Jiajun Liu6, Benjamin J Lee6, Michael N Neely7, Marc H Scheetz8.   

Abstract

The percentage of time that free drug concentrations remain above the MIC (fT>MIC) that is necessary to prevent mortality among cefepime-treated patients with Gram-negative bloodstream infections (GNBSI) is poorly defined. We conducted a retrospective study of adult patients with GNBSI. Eligible cases were frequency matched to ensure categorical representation from all MICs. Organism, MIC, infection source, gender, age, serum creatinine, weight, antibiotic history, and modified APACHE II score were collected from hospital records. Two population pharmacokinetic models (models 1 and 2) were used to impute exposures over the first 24 h in each patient from mean model parameters, covariates, and dosing history. From the imputed exposures, survival thresholds for fT>MIC were identified using classification and regression tree (CART) analysis and analyzed as nominal variables for univariate and multivariate regressions. A total of 180 patients were included in the analysis, of whom 13.9% died and 86.1% survived. Many patients (46.7% [n = 84/180]) received combination therapy with cefepime. Survivors had higher mean (standard deviation [SD]) fT>MIC than those who died (model 1, 74.2% [29.6%] versus 52.1% [33.8%], P < 0.001; model 2, 85.9% [24.0%] versus 64.4% [31.4%], P < 0.001). CART identified fT>MIC threshold values for greater survival according to models 1 and 2 at >68% and >74%, respectively. Survival was improved for those with fT>MIC of >68% (model 1 adjusted odds ratio [aOR], 7.12; 95% confidence interval [CI], 1.90 to 26.7; P = 0.004) and >74% (model 2 aOR, 6.48; 95% CI, 1.90 to 22.1) after controlling for clinical covariates. Similarly, each 1% increase in cefepime fT>MIC resulted in a 2% improvement in multivariate survival probability (P = 0.015). Achieving a cefepime fT>MIC of 68 to 74% was associated with a higher odds of survival for patients with GNBSI. Regimens targeting this exposure should be aggressively pursued.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26666929      PMCID: PMC4775983          DOI: 10.1128/AAC.01956-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Efficiency of case-control studies with multiple controls per case: continuous or dichotomous data.

Authors:  H K Ury
Journal:  Biometrics       Date:  1975-09       Impact factor: 2.571

Review 2.  Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

Authors:  George L Drusano
Journal:  Nat Rev Microbiol       Date:  2004-04       Impact factor: 60.633

3.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

Review 4.  Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations.

Authors:  D Andes; W A Craig
Journal:  Clin Microbiol Infect       Date:  2005-11       Impact factor: 8.067

5.  Evaluation of clinical outcomes in patients with Gram-negative bloodstream infections according to cefepime MIC.

Authors:  Nathaniel J Rhodes; Jiajun Liu; Milena M McLaughlin; Chao Qi; Marc H Scheetz
Journal:  Diagn Microbiol Infect Dis       Date:  2015-03-10       Impact factor: 2.803

Review 6.  Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.

Authors:  W A Craig
Journal:  Diagn Microbiol Infect Dis       Date:  1995 May-Jun       Impact factor: 2.803

7.  Effect of cefepime dose on mortality of patients with Gram-negative bacterial bloodstream infections: a prospective cohort study.

Authors:  Marcelle D Alves; Vanessa B Ribeiro; Jardel P Tessari; Francine Mattiello; Giordanna De Bacco; Daniela I Luz; Fabiane J Vieira; Tainá F Behle; Alessandro C Pasqualotto; Alexandre P Zavascki
Journal:  J Antimicrob Chemother       Date:  2014-01-27       Impact factor: 5.790

8.  Indications and Types of Antibiotic Agents Used in 6 Acute Care Hospitals, 2009-2010: A Pragmatic Retrospective Observational Study.

Authors:  Theodoros Kelesidis; Nikolay Braykov; Daniel Z Uslan; Daniel J Morgan; Sumanth Gandra; Birgir Johannsson; Marin L Schweizer; Scott A Weisenberg; Heather Young; Joseph Cantey; Eli Perencevich; Edward Septimus; Arjun Srinivasan; Ramanan Laxminarayan
Journal:  Infect Control Hosp Epidemiol       Date:  2015-10-12       Impact factor: 3.254

9.  Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia.

Authors:  Mark J Siedner; Alicia Galar; Belisa B Guzmán-Suarez; David W Kubiak; Nour Baghdady; Mary Jane Ferraro; David C Hooper; Thomas F O'Brien; Francisco M Marty
Journal:  Clin Infect Dis       Date:  2014-03-18       Impact factor: 9.079

Review 10.  Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.

Authors:  Rinaldo Bellomo; Claudio Ronco; John A Kellum; Ravindra L Mehta; Paul Palevsky
Journal:  Crit Care       Date:  2004-05-24       Impact factor: 9.097

View more
  18 in total

1.  Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats.

Authors:  Nathaniel J Rhodes; Walter C Prozialeck; Thomas P Lodise; Natarajan Venkatesan; J Nicholas O'Donnell; Gwendolyn Pais; Cameron Cluff; Peter C Lamar; Michael N Neely; Anil Gulati; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

2.  Is One Sample Enough? β-Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model.

Authors:  Ana Motos; Joseph L Kuti; Gianluigi Li Bassi; Antoni Torres; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

3.  Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing.

Authors:  Mohammad H Al-Shaer; Michael N Neely; Jiajun Liu; Kartikeya Cherabuddi; Veena Venugopalan; Nathaniel J Rhodes; Kenneth Klinker; Marc H Scheetz; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

Review 4.  What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.

Authors:  Chandra Datta Sumi; Aaron J Heffernan; Jeffrey Lipman; Jason A Roberts; Fekade B Sime
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

5.  Reporting Considerations for Cefepime-Susceptible and -Susceptible-Dose Dependent Results for Carbapenemase-Producing Enterobacterales.

Authors:  J A Fissel; M L Yarbrough; T Tekle; C A Burnham; P J Simner
Journal:  J Clin Microbiol       Date:  2020-08-24       Impact factor: 5.948

Review 6.  Individualising Therapy to Minimize Bacterial Multidrug Resistance.

Authors:  A J Heffernan; F B Sime; J Lipman; J A Roberts
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

7.  Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization.

Authors:  Christian M Gill; Elif Aktaş; Wadha Alfouzan; Lori Bourassa; Adrian Brink; Carey-Ann D Burnham; Rafael Canton; Yehuda Carmeli; Marco Falcone; Carlos Kiffer; Anna Marchese; Octavio Martinez; Spyros Pournaras; Harald Seifert; Abrar K Thabit; Maria Virginia Villegas; Lars F Westblade; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2021-08-16       Impact factor: 5.191

Review 8.  Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.

Authors:  Nikolas J Onufrak; Alan Forrest; Daniel Gonzalez
Journal:  Clin Ther       Date:  2016-07-20       Impact factor: 3.393

9.  Time above the MIC of Piperacillin-Tazobactam as a Predictor of Outcome in Pseudomonas aeruginosa Bacteremia.

Authors:  Elias Tannous; Shelly Lipman; Antonella Tonna; Emma Hector; Ziad Hussein; Michal Stein; Sharon Reisfeld
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

10.  Too Much of a Good Thing: Defining Antimicrobial Therapeutic Targets to Minimize Toxicity.

Authors:  Kevin J Downes; Jennifer L Goldman
Journal:  Clin Pharmacol Ther       Date:  2021-02-27       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.